Omar Hamid, MD

Chief, Translational Research and Immunotherapy, director, Melanoma Therapeutics, director, Melanoma Center and Phase I Immuno-Oncology Program, The Angeles Clinic and Research Institute

Articles by Omar Hamid, MD

Integrating TIL-Based Therapy into Melanoma Treatment: Omar Hamid, MD

ByOmar Hamid, MD

October 1st 2021

The chief of translational Research and immunotherapy at The Angeles Clinic and Research Institute discussed the integration of tumor infiltrating lymphocyte–based therapy into the melanoma armamentarium.

Omar Hamid, MD

Articles by Omar Hamid, MD

Integrating TIL-Based Therapy into Melanoma Treatment: Omar Hamid, MD

Latest Updated Articles

Trending on CGTlive®

Patients Treated With AskBio’s Limb-Girdle Muscular Dystrophy Gene Therapy AB-1003 Free of Serious Adverse Events at Up to 52 Weeks

CGTLive®’s Weekly Rewind – October 17, 2025

Patients Treated With Spur Therapeutics’ Gaucher Disease Gene Therapy FLT201 Maintain Clinical Benefit for Up to 2 Years